Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...
GlobalData on MSN5d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mDaiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...
Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...
Dai ichi Life Insurance Company Ltd decreased its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 13.6% during the 3rd quarter, ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
Dai-ichi Life Insurance Co. lost about ¥140 billion ($890 million) selling off bonds with longer maturities to prepare for ...
Brookstone Capital Management lifted its holdings in KeyCorp (NYSE:KEY – Free Report) by 6.3% in the fourth quarter, ...
Hosted on MSN6d
Dai-ichi Life financial leverage to remain below 23%The planned bonds are expected to have a call option after 10 years. Fitch Ratings anticipates Dai-ichi Life's financial ...
The broader Topix index settled 1.19 percent higher at 2,711.27. Automakers led the surge, with Honda Motor rising 1.4 percent while Toyota Motor and Subaru both gained around 3 percent.
TOKYO: Dai-ichi Life Insurance Co lost about 140 billion yen selling off bonds with longer maturities to prepare for higher ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback